|
基尼克萨制药有限公司
|
|
|
..................................................................................................................................................................
|
|
|
PROXY
STATEMENT |
|
|
..................................................................................................................................................................
|
|
|
股东年会
|
|
|
June 29, 2022,
9:30 a.m. Atlantic Time (8:30 a.m. Eastern Time) |
|
| 股东周年大会通知 | | | | | | | |
|
代理对账单摘要
|
| | | | 1 | | |
|
Proxy Statement
|
| | | | 3 | | |
|
Proposals
|
| | | | 3 | | |
|
董事会的建议
|
| | | | 4 | | |
|
有关此代理声明的信息
|
| | | | 4 | | |
|
股东年会问答
|
| | | | 5 | | |
|
Proposals to be Voted On
|
| | | | 9 | | |
|
提案1: 董事选举
|
| | | | 9 | | |
|
建议2: 任命审计师,通过我们的
委派给我们的董事会
审计委员会,负责确定审计师的薪酬,以及 批准独立注册会计师任命 Firm |
| | |
|
13
|
| |
|
提案3: 对高管薪酬的咨询投票
|
| | | | 14 | | |
|
董事会审计委员会报告
|
| | | | 16 | | |
|
独立注册会计师事务所收费及其他事宜
|
| | | | 17 | | |
|
Corporate Governance
|
| | | | 18 | | |
|
General
|
| | | | 18 | | |
|
Board Composition
|
| | | | 18 | | |
|
Board Diversity
|
| | |
|
18
|
| |
|
董事独立
|
| | | | 19 | | |
|
Director Candidates
|
| | | | 19 | | |
|
股东的沟通信息
|
| | | | 20 | | |
|
董事会领导结构
|
| | | | 20 | | |
|
董事会在风险监督中的作用
|
| | | | 21 | | |
|
Board Evaluation
|
| | | | 21 | | |
|
Code of Ethics
|
| | | | 22 | | |
|
内幕交易合规政策
|
| | | | 22 | | |
|
董事会成员出席会议情况
|
| | | | 22 | | |
|
Committees of the Board
|
| | | | 23 | | |
|
Audit Committee
|
| | | | 23 | | |
|
薪酬委员会
|
| | | | 24 | | |
|
提名和公司治理委员会
|
| | | | 24 | | |
|
科学研究委员会
|
| | | | 25 | | |
|
Executive Officers
|
| | | | 26 | | |
|
高管和董事薪酬
|
| | | | 28 | | |
|
高管薪酬
|
| | | | 28 | | |
|
2021薪酬汇总表
|
| | |
|
28
|
| |
|
薪酬汇总表的叙述性披露
|
| | | | 28 | | |
|
2021财年年底杰出股权奖
|
| | |
|
33
|
| |
|
雇佣协议
|
| | | | 34 | | |
|
董事薪酬
|
| | | | 36 | | |
|
2021董事薪酬表
|
| | | | 37 | | |
|
股权薪酬计划信息
|
| | | | 38 | | |
|
某些受益所有者和管理层的安全所有权
|
| | | | 39 | | |
|
某些关系
|
| | | | 42 | | |
|
Other Matters
|
| | | | 44 | | |
|
Shareholders’ Proposals
|
| | | | 44 | | |
|
将在年会上提交的其他事项
|
| | | | 44 | | |
|
代理征集
|
| | | | 45 | | |
|
Kiniksa年度报告Form 10-K
|
| | |
|
45
|
| |
|
Date and Time:
|
| | 2022年6月29日星期三上午9:30大西洋时间(上午8:30东部时间) | |
|
Location:
|
| | 在线虚拟会议,网址为www.VirtualSharholderMeeting.com/KNSA2022 | |
|
Record Date:
|
| | April 14, 2022 | |
|
Proposal
|
| |
Votes required
|
| |
被扣留/弃权的投票效果
and broker non-votes |
|
| 提案1-选举董事 | | | 投票的多数票。这意味着获得赞成票最多的三位被提名人将被选为I类董事。 | | | 被扣留的投票和代理非投票将不起作用。 | |
| 提案2--任命审计师,授权制定审计师薪酬,并批准任命独立注册会计师事务所 | | | 占多数投票权的人对所投赞成票或反对票投的赞成票。 | | | 弃权无效。我们预计不会有任何经纪人对这项提议投反对票。 | |
| 提案3-在咨询(非约束性)基础上批准我们指定的高管的薪酬 | | | 占多数投票权的人对所投赞成票或反对票投的赞成票。 | | | 弃权票和经纪人反对票无效。 | |
|
|
| |
董事会一致建议投票选举
董事一级提名名单紧随其后。 |
|
|
Name
|
| |
Age
|
| |
Served as a
Director Since |
| |
Position(s) with Kiniksa
|
|
| Sanj K. Patel | | |
52
|
| |
2015
|
| | 首席执行官兼董事会主席 | |
| Thomas R. Malley | | |
53
|
| |
2016
|
| | Director | |
| Richard S. Levy, M.D. | | |
64
|
| |
2019
|
| | Director | |
|
|
| |
SANJ K. PATEL
|
| |
52岁
|
|
|
|
| |
THOMAS R. MALLEY
|
| |
53岁
|
|
|
|
| |
RICHARD S. LEVY, M.D.
|
| |
64岁
|
|
|
Name
|
| |
Age
|
| |
Served as a
Director Since |
| |
Position with Kiniksa
|
|
| STEPHEN R. BIGGAR, M.D., PH.D. | | |
51
|
| |
2015
|
| | Director | |
| G. BRADLEY COLE | | |
66
|
| |
2020
|
| | Director | |
| BARRY D. QUART, PHARM.D. | | |
65
|
| |
2015
|
| | Director | |
|
|
| |
STEPHEN R. BIGGAR, M.D., PH.D.
|
| |
51岁
|
|
|
|
| |
G. BRADLEY COLE
|
| |
66岁
|
|
|
|
| |
BARRY D. QUART PHARM.D.
|
| |
65岁
|
|
|
Name
|
| |
Age
|
| |
Served as a
Director Since |
| |
Position with Kiniksa
|
|
| Felix J. Baker, Ph.D. | | |
53
|
| |
2015
|
| | Director | |
| Tracey L. McCain | | |
54
|
| |
2018
|
| | Director | |
| Kimberly J. Popovits | | |
63
|
| |
2018
|
| | Director | |
|
|
| |
FELIX J. BAKER, PH.D.
|
| |
53岁
|
|
|
|
| |
TRACEY L. MCCAIN
|
| |
54岁
|
|
|
|
| |
KIMBERLY J. POPOVITS
|
| |
63岁
|
|
|
|
| |
董事会一致建议投票通过任命普华永道会计师事务所为我们的审计师,直至我们的下一届年度股东大会结束,通过我们的审计委员会授权我们的董事会制定该期间审计师的薪酬,并批准任命普华永道会计师事务所为我们截至2022年12月31日的财政年度的独立注册会计师事务所。
|
|
|
|
| |
董事会根据美国证券交易委员会适用的薪酬披露规则,一致建议就公司2022年年会委托书中披露的我们任命的高管的薪酬进行投票,包括薪酬表格和叙述性讨论。
|
|
|
Fee Category
|
| |
2021
|
| |
2020
|
|
| Audit Fees | | |
$971,000
|
| |
$1,111,500
|
|
| Audit-Related Fees | | |
$0
|
| |
$0
|
|
| Tax Fees | | |
$0
|
| |
$0
|
|
| All Other Fees | | |
$2,956
|
| |
$2,700
|
|
| Total Fees | | |
$973,956
|
| |
$1,114,200
|
|
| |
Board Diversity Matrix (as of April 28, 2022)
|
| | ||||||||||||||||
| |
Total Number of
Directors |
| | |
9
|
| | ||||||||||||
| | | | | | Female | | | | Male | | | | Non-Binary | | | |
Did not
Disclose Gender Identity |
| |
| | 第一部分:性别认同 | | | ||||||||||||||||
| | Directors | | | |
2
|
| | |
7
|
| | |
-
|
| | |
-
|
| |
| | 第二部分:人口多样性 | | | ||||||||||||||||
| |
African American
or Black (not of Hispanic or Latinx origin) |
| | |
1
|
| | |
-
|
| | |
-
|
| | |
-
|
| |
| |
Alaskan Native or
Native American |
| | |
-
|
| | |
-
|
| | |
-
|
| | |
-
|
| |
| | Asian | | | | | | | |
1
|
| | | | | | | | | |
| |
Hispanic or Latinx
|
| | |
-
|
| | |
-
|
| | |
-
|
| | |
-
|
| |
| |
Native Hawaiian
or Pacific Islander |
| | |
-
|
| | |
-
|
| | |
-
|
| | |
-
|
| |
| |
White (not of
Hispanic or Latinx origin) |
| | |
1
|
| | |
6
|
| | |
-
|
| | |
-
|
| |
| |
Two or More
Races or Ethnicities |
| | |
-
|
| | |
-
|
| | |
-
|
| | |
-
|
| |
| | LGBTQ+ | | | |
-
|
| | ||||||||||||
| |
Did not Disclose
Demographic Background |
| | |
-
|
| |
|
Name
|
| |
Audit
|
| |
Compensation
|
| |
Nominating
and Corporate Governance |
| |
Science
and Research |
|
| Felix J. Baker, Ph.D. | | | | | |
Chair
|
| |
X
|
| |
X
|
|
|
Stephen R. Biggar, M.D., Ph.D.
|
| | | | | | | |
Chair
|
| |
X
|
|
| G. Bradley Cole | | |
X
|
| | | | | | | | | |
| Richard S. Levy | | | | | | | | | | | |
Chair
|
|
| Thomas R. Malley | | |
Chair
|
| | | | |
X
|
| | | |
| Tracey McCain* | | |
X
|
| | | | | | | | | |
| Kimberly J. Popovits | | | | | |
X
|
| | | | | | |
| Barry D. Quart, Pharm.D. | | |
X
|
| |
X
|
| | | | | | |
|
Name
|
| |
Age
|
| |
Position
|
|
| Sanj K. Patel | | |
52
|
| | 首席执行官兼董事会主席 | |
| Michael Megna | | |
51
|
| |
集团副总裁、财务兼首席会计官
|
|
| Ross Moat | | |
41
|
| | 高级副总裁兼首席商务官 | |
|
John F. Paolini, M.D., Ph.D.
|
| |
57
|
| | 高级副总裁兼首席医疗官 | |
| Mark Ragosa | | |
48
|
| | 高级副总裁兼首席财务官 | |
| Eben Tessari | | |
40
|
| | 高级副总裁兼首席运营官 | |
|
姓名和主要职务
|
| |
Year
|
| |
Salary
($) |
| |
Share
awards ($)(3) |
| |
Option
awards ($)(3) |
| |
Non-equity
incentive plan compensation ($) |
| |
All other
compensation ($)(4) |
| |
Total
($) |
|
|
Sanj K. Patel(1)
首席执行官兼董事会主席
|
| |
2021
|
| |
803,400
|
| |
1,183,978
|
| |
3,795,238
|
| |
793,962
|
| |
11,600
|
| |
6,588,178
|
|
|
2020
|
| |
780,000
|
| |
—
|
| |
3,888,414
|
| |
633,750
|
| |
11,400
|
| |
5,313,564
|
| |||
|
John F. Paolini, M.D.
高级副总裁兼首席医疗官
|
| |
2021
|
| |
456,393
|
| |
321,368
|
| |
996,606
|
| |
242,863
|
| |
11,600
|
| |
2,028,830
|
|
|
Arian Pano, M.D.(2)
高级副总裁兼首席临床开发官
|
| |
2021
|
| |
436,000
|
| |
204,677
|
| |
561,493
|
| |
158,340
|
| |
11,600
|
| |
1,372,110
|
|
|
Name
|
| |
January 1, 2021
Annual Base Salary ($) |
|
|
Sanj K. Patel
|
| |
803,400
|
|
|
John F. Paolini, M.D.
|
| |
456,393
|
|
|
Arian Pano, M.D.
|
| |
436,000
|
|
|
被任命为执行干事
|
| |
March 2021
share options granted |
| |
March 2021
RSUs granted |
| |
September 2021
share options granted |
| |
September 2021
RSUs granted |
|
|
Sanj K. Patel
|
| |
157,658
|
| |
26,276
|
| |
157,658
|
| |
26,276
|
|
|
John F. Paolini, M.D.
|
| |
41,400
|
| |
6,900
|
| |
41,400
|
| |
6,900
|
|
|
Arian Pano, M.D.
|
| |
23,325
|
| |
3,888
|
| |
23,325
|
| |
3,888
|
|
|
Name
|
| | | | |
Option awards(1)
|
| |
Stock awards(1)
|
| ||||||||||||||||||
|
Vesting
start date |
| |
Number of
securities underlying unexercised options (#) exercisable |
| |
Number of
securities underlying unexercised options (#) unexercisable |
| |
Option
exercise price ($) |
| |
Option
expiration date |
| |
Number of
shares or units of stock that have not vested (#) |
| |
Market
value of shares or units of stock that have not vested ($)(2) |
| | | |||||||
|
Sanj K. Patel
|
| |
8/1/2015
|
| |
325,271
|
| |
—
|
| |
1.59
|
| |
12/15/2025
|
| |
—
|
| |
—
|
| | | ||||
|
6/29/2017
|
| |
257,969
|
| |
—
|
| |
3.80
|
| |
6/28/2027
|
| |
—
|
| |
—
|
| | | |||||||
|
3/1/2018
|
| |
263,510
|
| |
175,672(3)
|
| |
10.36
|
| |
2/29/2028
|
| |
—
|
| |
—
|
| | | |||||||
|
9/20/2018
|
| |
101,563
|
| |
23,437(4)
|
| |
30.93
|
| |
9/19/2028
|
| |
—
|
| |
—
|
| | | |||||||
|
3/4/2019
|
| |
128,565
|
| |
58,435(4)
|
| |
17.92
|
| |
3/3/2029
|
| |
—
|
| |
—
|
| | | |||||||
|
9/17/2019
|
| |
106,877
|
| |
83,123(4)
|
| |
8.83
|
| |
9/16/2029
|
| |
—
|
| |
—
|
| | | |||||||
|
3/13/2020
|
| |
78,752
|
| |
101,248(4)
|
| |
15.52
|
| |
3/12/2030
|
| |
—
|
| |
—
|
| | | |||||||
|
9/10/2020
|
| |
56,251
|
| |
123,749(4)
|
| |
15.50
|
| |
9/9/2030
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
157,658(4)
|
| |
22.89
|
| |
3/15/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
26,276(5)
|
| |
309,269
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
18,555(6)
|
| |
218,392
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
12,002(7)
|
| |
141,264
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
157,658(4)
|
| |
12.97
|
| |
9/1/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
26,276(5)
|
| |
309,269
|
| | | |||||||
|
John F. Paolini, M.D.
|
| |
9/14/2016
|
| |
197,574
|
| |
—
|
| |
1.86
|
| |
9/13/2026
|
| |
—
|
| |
—
|
| | | ||||
|
6/29/2017
|
| |
66,542
|
| |
—
|
| |
3.80
|
| |
6/28/2027
|
| |
—
|
| |
—
|
| | | |||||||
|
3/1/2018
|
| |
76,857
|
| |
51,237(3)
|
| |
10.36
|
| |
2/29/2028
|
| |
—
|
| |
—
|
| | | |||||||
|
9/20/2018
|
| |
36,563
|
| |
8,437(4)
|
| |
30.93
|
| |
9/19/2028
|
| |
—
|
| |
—
|
| | | |||||||
|
3/4/2019
|
| |
35,063
|
| |
15,937(4)
|
| |
17.92
|
| |
3/3/2029
|
| |
—
|
| |
—
|
| | | |||||||
|
9/17/2019
|
| |
25,876
|
| |
20,124(4)
|
| |
8.83
|
| |
9/16/2029
|
| |
—
|
| |
—
|
| | | |||||||
|
3/13/2020
|
| |
21,876
|
| |
28,124(4)
|
| |
15.52
|
| |
3/12/2030
|
| |
—
|
| |
—
|
| | | |||||||
|
9/10/2020
|
| |
15,626
|
| |
34,374(4)
|
| |
15.50
|
| |
9/9/2030
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
41,400(4)
|
| |
22.89
|
| |
3/15/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
6,900(5)
|
| |
81,213
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
5,676(6)
|
| |
66,807
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
3,671(7)
|
| |
43,208
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
41,400(4)
|
| |
12.97
|
| |
9/1/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
6,900(5)
|
| |
81,213
|
| | | |||||||
|
Arian Pano, M.D.
|
| |
12/2/2019
|
| |
52,085
|
| |
47,915(4)
|
| |
10.14
|
| |
12/1/2029
|
| |
—
|
| |
—
|
| | | ||||
|
3/13/2020
|
| |
13,126
|
| |
16,874(4)
|
| |
15.52
|
| |
3/12/2030
|
| |
—
|
| |
—
|
| | | |||||||
|
9/10/2020
|
| |
9,376
|
| |
20,624(4)
|
| |
15.50
|
| |
9/9/2020
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
23,325(4)
|
| |
22.89
|
| |
3/15/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
3,888(5)
|
| |
45,762
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
4,867(6)
|
| |
57,285
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
3,240(7)
|
| |
38,135
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
23,325(4)
|
| |
12.97
|
| |
9/1/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
3,888(5)
|
| |
45,762
|
| | |
|
Name
|
| |
Fees
earned or paid in cash ($) |
| |
Option
awards ($)(1) |
| |
Total ($)
|
|
|
Felix J. Baker, Ph.D.
|
| |
92,987
|
| |
297,936
|
| |
390,923
|
|
|
Stephen R. Biggar, M.D., Ph.D.
|
| |
53,887
|
| |
297,936
|
| |
351,823
|
|
|
G. Bradley Cole
|
| |
49,000
|
| |
297,936
|
| |
346,936
|
|
|
Richard S. Levy, M.D.
|
| |
49,755
|
| |
297,936
|
| |
347,691
|
|
|
Thomas R. Malley
|
| |
64,000
|
| |
297,936
|
| |
361,936
|
|
|
Tracey L. McCain
|
| |
40,000
|
| |
297,936
|
| |
337,936
|
|
|
Kimberly J. Popovits
|
| |
46,300
|
| |
297,936
|
| |
344,236
|
|
|
Barry D. Quart, Pharm.D
|
| |
55,300
|
| |
297,936
|
| |
353,236
|
|
|
Name
|
| |
Option
awards(#) |
|
|
Felix J. Baker, Ph.D.
|
| |
89,517
|
|
|
Stephen R. Biggar, M.D., Ph.D.
|
| |
89,517
|
|
|
G. Bradley Cole
|
| |
71,202
|
|
|
Richard S. Levy, M.D.
|
| |
89,962
|
|
|
Thomas R. Malley
|
| |
140,293
|
|
|
Tracey L. McCain
|
| |
116,505
|
|
|
Kimberly J. Popovits
|
| |
116,505
|
|
|
Barry D. Quart, Pharm.D
|
| |
140,293
|
|
|
Plan Category
|
| |
Number of
Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights |
| |
Weighted
Average Exercise Price of Outstanding Options Warrants and Rights |
| |
Number of
Securities Available for Future Issuance Under Equity Compensation Plans(1) |
|
| 证券持有人批准的股权补偿计划(2) | | |
10,111,867(3)
|
| |
$14.14(4)
|
| |
4,945,891(5)
|
|
| 股权补偿计划未经证券持有人批准 | | |
—
|
| |
—
|
| |
—
|
|
|
Total
|
| |
10,111,867
|
| |
$14.14
|
| |
4,945,891
|
|
| | | |
Class A
common shares |
| |
Class A
common shares % |
| |
Class A1
common shares |
| |
Class A1
common shares % |
| |
Class B
common shares |
| |
Class B
common shares % |
| |
Class B1
common shares |
| |
Class B1
common shares % |
| |
% of total
voting power |
|
| 5%的股东 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
Baker Bros.Advisors LP管理的实体(1)
|
| |
2,978,611
|
| |
8.65%
|
| |
12,781,964
|
| |
74.62%
|
| |
—
|
| |
—
|
| |
16,057,618
|
| |
100.00%
|
| |
5.66%
|
|
|
高瓴附属实体(2)
|
| |
2,920,023
|
| |
8.52%
|
| |
4,347,639
|
| |
25.38%
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
5.57%
|
|
|
Vanguard Group(3)
|
| |
2,890,708
|
| |
8.43%
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
5.52%
|
|
| 隶属于Pictet Asset Management S.A.的实体(4) | | |
3,548,649
|
| |
10.35%
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
6.77%
|
|
|
贝莱德所属实体
Inc.(5) |
| |
3,483,852
|
| |
10.17%
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
6.65%
|
|
| 与Robert Desnick博士有关联的实体(6) | | |
1,053,962
|
| |
3.08%
|
| |
—
|
| |
—
|
| |
214,101
|
| |
11.81%
|
| |
214,101
|
| |
1.32%
|
| |
6.10%
|
|
| 高级职员和董事 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
Sanj K. Patel(7)
|
| |
1,788,834
|
| |
4.99%
|
| |
—
|
| |
—
|
| |
1,526,160
|
| |
84.16%
|
| |
1,526,160
|
| |
8.68%
|
| |
31.58%
|
|
|
John F. Paolini, M.D.(8)
|
| |
791,724
|
| |
2.26%
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
1.49%
|
|
|
Arian Pano, M.D.(9)
|
| |
155,793
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Felix J. Baker, Ph.D.(1)(10)
|
| |
3,000,771
|
| |
8.71%
|
| |
12,781,964
|
| |
74.62%
|
| |
—
|
| |
—
|
| |
16,057,618
|
| |
100.00%
|
| |
5.71%
|
|
|
Stephen R. Biggar, M.D., Ph.D.(1)
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
|
|
G. Cole Bradley(11)
|
| |
71,202
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Richard S. Levy(12)
|
| |
89,962
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Thomas R. Malley(13)
|
| |
212,260
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Tracey L. McCain(14)
|
| |
116,505
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Kimberly J. Popovits(15)
|
| |
116,505
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Barry D. Quart, Pharm. D.(16)
|
| |
140,293
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
全体现任执行干事和董事(14人)(17)
|
| |
7,437,477
|
| |
18.64%
|
| |
12,781,964
|
| |
74.62%
|
| |
1,526,160
|
| |
84.16%
|
| |
16,057,618
|
| |
100.00%
|
| |
40.20%
|
|